Arcinova has now been rebranded to Quotient Sciences
NOTTINGHAM, U.K.; July 1, 2021 – Quotient Sciences, the drug development and manufacturing accelerator, announces that it has completed the rebrand of Arcinova, the Alnwick U.K.-based contract development and manufacturing organization (CDMO). Now called Quotient Sciences - Alnwick, the site has significant expertise in drug substance manufacture, isotope labelling, bioanalysis and drug product development, playing a key role in strengthening Quotient’s services portfolio from candidate selection to commercial manufacturing.
Quotient acquired Arcinova in February 2021 with the strategic goal of providing an “end to end” offering for customers and creating further differentiation for Quotient in the marketplace. The combined business uniquely supports customers with drug substance, drug product and clinical testing capabilities all under one organization. “By cutting through silos and integrating these capabilities, Quotient simplifies outsourcing for customers and creates substantial timeline acceleration,” said Mark Egerton, CEO of Quotient Sciences. This differentiation extends the 12-month drug development time savings already delivered by Quotient’s flagship platform Translational Pharmaceutics®.
Quotient strives to help customers save time and money in the pharmaceutical development process and the combined business has already identified several new integrated service packages that will be offered to customers in the coming months. These integrated programs include a holistic candidate selection offering and a streamlined program that fully integrates drug substance and drug product manufacturing.